Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pringgodigdo Nugroho has a total of 139 co-authors. Here are the top co-authors by number of shared publications:

  • Aida Lydia

    Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

    5 shared publications
  • Aida Lydia

    Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia—Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia

    3 shared publications
  • Anandhara Indriani Khumaedi

    Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia

    2 shared publications
  • Evy Yunihastuti

    Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia

    2 shared publications
  • Fidel Hermanto

    Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia—Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia

    2 shared publications
  • Hamzah Shatri

    Faculty of Medicine Universitas Indonesia

    2 shared publications

Latest Publications

  • Open Access

    Circulating miRNA-21 and Biomarkers of Inflammation, Fibrosis, and Oxidative Stress in Adults with Type 2 Diabetes Mellitus: A Cross-Sectional Study

    by Pringgodigdo Nugroho, Angeline Tancherla, Em Yunir, Vika Wirdhani, Anandhara Indriani Khumaedi, Renny Ary Soetedjo, Muhammad Jalaluddin Rumi

    Purpose: Chronic inflammation, oxidative stress, and fibrosis are interconnected drivers of complications in type 2 diabetes mellitus (T2DM) and may precede detectable changes in conventional clinical markers. MicroRNA-21 (miR-21) has been implicated in all three pathways, but its associations with representative biomarkers have rarely been examined simultaneously in a single T2DM population. We evaluated correlations between circulating miR-21 and serum tumor necrosis factor receptor-1 (TNFR1), transforming growth factor-beta 1 (TGF-β 1), and 8-hydroxy-2′-deoxyguanosine (8-OHdG), and explored differences by albuminuria status. Patients and Methods: This cross-sectional study was a secondary analysis of clinical data and archived serum from 54 adults with T2DM enrolled in the Bogor Non-Communicable Disease Risk Factor Cohort, Indonesia. Most participants had preserved kidney function (mean eGFR 76.9 ± 15.0 mL/min/1.73m2; 63.0% without albuminuria). Circulating miR-21 was quantified by quantitative real-time PCR; TNFR1, TGF-β 1, and 8-OHdG were measured by ELISA. Independent associations were evaluated using multivariable linear regression adjusted for age, sex, BMI, HbA1c, LDL cholesterol, and eGFR. Bootstrap resampling and albuminuria-stratified analyses were performed. Results: Log2-transformed miR-21 correlated weakly with log2 TNFR1 (ρ = 0.273, P = 0.046) and remained independently associated with TNFR1 after adjustment (β = 0.061, 95% CI 0.001– 0.122, P = 0.048). This borderline association was robust to bootstrap resampling and additional adjustment for diabetes duration and statin use. No independent associations were observed with TGF-β 1 or 8-OHdG overall. Exploratory findings showed that miR-21 was associated with TGF-β 1 among participants with albuminuria (β = 0.286, P = 0.038), but the interaction was not significant (P = 0.087). Conclusion: In this T2DM population with predominantly preserved kidney function, circulating miR-21 was associated with TNFR1, a marker of TNF-α–related inflammatory activity, but not with TGF-β 1 or 8-OHdG. These exploratory findings, limited by the small sample, borderline statistical significance, and lack of multiplicity adjustment, require confirmation in larger prospective, multicenter studies.

  • Open Access

    Characterization of Spent Coffee Grounds’ Polyphenol Fraction and Its Potential as a Low-Cost Tool for Bioactivity-Guided Nephroprotective Modulation of Gut–Kidney Axis and NF-κB/Nrf2/TGF-β Signaling in Hypertension-Associated Kidney Injury

    by Fahrul Nurkolis, Dante Saksono Harbuwono, Yulia Wardhani, Edwin Hadinata, Siti Nur Rohmah, Metalia Puspitasari, Lucia De Luca, Raffaele Romano, Danny Pratama Kuswadi, Raymond Rubianto Tjandrawinata, et al.

    Background: Hypertension-associated kidney injury is driven by oxidative stress, inflammation, fibrosis, and gut-derived uremic toxins via the gut–kidney axis. Spent coffee grounds (SCG) represent a sustainable source of bioactive polyphenols with potential nephroprotective effects. This study aimed to characterize a bioactivity-guided SCG polyphenol fraction and evaluate its therapeutic potential. Methods: Bioactivity-guided fractionation was performed to enrich active polyphenols, followed by in silico target prediction and in vivo validation using L-NAME-induced hypertensive rats treated for 8 weeks. Renal function, oxidative stress, inflammatory and fibrotic markers, gut-derived metabolites, and endothelial function were assessed. Results: The enriched fraction was dominated by chlorogenic acid derivatives and showed predicted interactions with NF-κB, Keap1/Nrf2, TGF-β receptor, ACE, and AT1 receptor. In hypertensive rats, treatment significantly lowered blood pressure, improved renal function, reduced oxidative stress, inflammation, fibrosis, and gut-derived uremic toxins, while restoring Nrf2 activity, short-chain fatty acid production, and endothelial function. Across multiple biological endpoints, the polyphenol-enriched fraction consistently demonstrated greater efficacy than the crude extract. Conclusions: SCG polyphenol fraction shows strong nephroprotective potential via gut–kidney axis modulation and NF-κB/Nrf2/TGF-β regulation, supporting its development as a low-cost therapeutic candidate.


    • 1 January 2026
      • Vol. 58  (1) , 123-132

    Expert Opinion on the Management of Hyperkalemia in Patients with Cardiorenal Diseases Treated with Renin Angiotensin Aldosterone System Inhibitors: An Indonesian Perspective.

    by Pringgodigdo Nugroho, Aida Lydia, Haerani Abdul Rasyid, Zulkhair Ali, Pranawa Pranawa, Nyoman Paramita Ayu, Birry Karim, Erwin Sukandi, Siti Elkana Nauli, Hary Sakti Muliawan, et al.

    Hyperkalemia (serum potassium >5.0 mEq/l) is a significant complication in patients with heart failure, chronic kidney disease, and diabetes mellitus, particularly when treated with renin-angiotensin-aldosterone system inhibitors (RAASi). Both hyperkalemia and RAASi interruption are associated with increased cardiovascular events, hospitalizations, and mortality. This expert opinion document, developed between January and December 2024 through a systematic process, aims to establish guidance for hyperkalemia treatment in Indonesian patients with cardiorenal diseases receiving RAASi therapy, addressing the unique challenges within the Indonesian healthcare context. A comprehensive literature review of international guidelines and regional studies was conducted by a panel of 11 expert specialists (3 cardiologists, 6 internist-nephrologists, and 2 internist-cardiologists), who evaluated 29 statements covering diagnosis, monitoring, prevention, and treatment of hyperkalemia. Of the 29 statements, 26 reached consensus: 17 statements achieved very high agreement (≥90%) and 9 attained high agreement (≥67% - <90%). The agreed statements covered key areas, including potassium monitoring frequency, RAASi dose optimization strategies, dietary modifications, and treatment thresholds. Three statements regarding alternative therapeutic approaches did not receive agreement (<67%) due to limited local availability and cost considerations. Key recommendations include structured monitoring protocols for high-risk patients, strategies for RAASi dose optimization while managing hyperkalemia risk, and specific interventions adapted to local resources. This document provides a practical approach for managing hyperkalemia in Indonesian patients with cardiorenal diseases while maintaining optimal RAASi therapy, considering local Indonesian healthcare resources and constraints.

  • Open Access

    Improving Renal Protection in Chronic Kidney Disease Associated with Type 2 Diabetes: The Role of Finerenone

    by Pringgodigdo Nugroho

    Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2D), which often leads to diabetic kidney disease (DKD). Traditional therapies, including renin- angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter-2 inhibitors, are effective in slowing CKD progression. However, these approaches are insufficient to comprehensively inhibit mineralocorticoid receptor (MR) overactivation in the kidneys, which remains a significant driver of inflammation, fibrosis, and oxidative stress. These pathological processes accelerate kidney damage and cardiovascular complications. Finerenone-a nonsteroidal mineralocorticoid receptor antagonist-represents a new frontier in renal protection. Unlike steroidal mineralocorticoid antagonists (MRAs), finerenone offers a more selective MR blockade, reducing kidney inflammation and fibrosis without significantly raising serum potassium levels. Landmark trials have demonstrated the ability of finerenone to significantly reduce kidney and cardiovascular events in patients with T2D and CKD. Clinical evidence has highlighted finerenone as an effective option for slowing DKD progression while maintaining a favorable safety profile. Based on these findings, recent guidelines have incorporated finerenone as a recommended therapy for patients with T2D and CKD, emphasizing its role in reducing both renal and cardiovascular risks. This review provides a comprehensive overview of the available data to offer a deeper understanding of the potential of finerenone to transform CKD management for T2D patients.


  • Open Access

    Modulation of renal inflammation and tubular injury by calcitriol in patients with early diabetic kidney disease: a randomized controlled trial

    by Pringgodigdo Nugroho, Aida Lydia, Pradana Soewondo, Ina Susianti Timan, Kuntjoro Harimurti, Zulkhair Ali

    Diabetic kidney disease (DKD) is marked by inflammation, fibrosis and oxidative stress. Calcitriol may offer renoprotective effects by modulating these processes. This double-blind, randomized controlled trial investigated the effects of calcitriol supplementation on kidney injury biomarkers in patients with early DKD. This study randomized 120 patients with controlled type 2 diabetes, albuminuria, and estimated glomerular filtration rate above 45 mL/min/1.73 m2 to receive either 0.25 mcg/d calcitriol or a placebo for six months. The primary outcomes were changes in urinary nephrin, podocin, kidney injury molecule-1 (KIM-1), interleukin-6 (IL-6), and urinary albumin-to-creatinine ratio (UACR). After 6 months, the calcitriol group showed lower increases in IL-6 levels (baseline 0.72 pg/mL to 0.87 pg/mL) compared to placebo (1.03 pg/mL to 2.94 pg/mL, p = 0.006), and lower KIM-1 levels (0.36 to 0.51 ng/mL vs. 0.55 to 0.99 ng/mL, p = 0.020). Full baseline and post-treatment values are provided in Tables 2. Urinary nephrin levels decreased in the calcitriol group, while change in the placebo group varied. Although UACR decreased more in the calcitriol group, the difference was not statistically significant (p = 0.099). Positive correlations were observed between KIM-1 and IL-6 in both groups, and a moderate correlation between IL-6 and urinary nephrin was observed in in the calcitriol group. No significant adverse events or changes in serum calcium or phosphate levels were reported. These findings suggest that Calcitriol supplementation may provide renoprotection in patients with early DKD by reducing inflammation and tubular injury, with potential effects on podocyte injury. Further research is required to validate these effects and determine the optimal dosing regimens. ClinicalTrials.gov (NCT05298163).


  • Open Access

    Decline in estimated glomerular filtration rate following substitution of Nevirapine-based regimen with Tenofovir-based regimen in Indonesia

    by Evy Yunihastuti, Pringgodigdo Nugroho, Muhammad Yusuf, Salfia Dian Lastari, Fadlika Harinda, Tiara Kumala Putri, Meivina Ramadhani Pane, Metra Adi Pratama, Mira Yulianti, Alvina Widhani, et al.

    Indonesia started transitioning people living with HIV (PLHIV) from Nevirapine (NVP)-based antiretroviral therapy to tenofovir (TDF)-lamivudine-dolutegravir fixed-dose combination (TLD) in 2023. We aimed to evaluate changes in estimated glomerular filtration rate (eGFR) and predictors of rapid eGFR decline within 6 months during this programmatic dolutegravir (DTG) transition. This prospective observational study included all adult PLHIV (≥ 18 years old) who received an NVP-based regimen initially, had baseline eGFR of more than 60 mL/min/1.73m2 before the transition, and underwent the DTG transition program in Cipto Mangunkusumo Hospital from March 2023 to January 2024. Participants who did not have at least two eGFR measurements were not included in the study. The decline in the eGFR during the study period was defined by a minimum 25% eGFR decline from baseline, and multivariate regression was used for analysis. A total of 329 participants were transitioned to TLD. Of these patients, 242 (73.6%) transitioned from the zidovudine-lamivudine fixed-dose combination and NVP (AZT/3TC+NVP), and 87 (26.4%) transitioned from TDF+3TC+NVP. Within six months of observation, 87.2% of participants had eGFR decline. Sixty-one participants (18.5%) experienced rapid eGFR decline: 19.8% and 14.9% in those who had previously used AZT and TDF, respectively. Factors related to rapid eGFR decline were hypertension (aRR 1.87; 95% CI: 1.15 – 3.05) and longer usage of previous ART (aRR 1.05; 95% CI: 1.01 – 1.10). Rapid eGFR decline after transitioning from an NVP-based regimen to TLD warrants close monitoring, especially in patients with hypertension and longer use of ART.


    • 1 October 2025
      • Vol. 57  (4) , 531-537

    Perspective of Muslims on Kidney Transplantation in Indonesia: A Narrative Review.

    by Maruhum Bonar Hasiholan Marbun, Jesslyn Mellenia, R Mohamad Javier, Dina Elita, Nur Rasyid, Pringgodigdo Nugroho

    The prevalence of end-stage renal disease patients in Indonesia is predicted to increase by the end of 2025. Kidney transplantation is the preferred treatment for end-stage renal disease, and the demand for kidney transplants is steadily increasing globally, including in Indonesia. However, organ transplantation and donation are debatable issues in the medical field, particularly when considered in conjunction with religious views. The Qur'an and Hadith do not directly discuss transplantation in Islam, prompting several interpretations and fatwas. Diverse ideologies, cultures, and beliefs also result in prospective differences. To address these differences, fatwas regarding the permissible conditions for transplantation have been issued by the Indonesian Ulema Council. This study aimed to explore the perspectives of Muslims and Islamic law on kidney transplantation in Indonesia. The study also includes comparative studies of Muslim perspectives from different countries. The findings provide an overview of Islamic law, the perspectives of religious scholars, and the perspectives of Muslims residing in Indonesia, as well as in other countries.

  • Open Access

    Association of Beta-2 Microglobulin Concentrations with Frailty in Patients Undergoing Chronic Hemodialysis

    by Pringgodigdo Nugroho, Nur Hidayat, Kuntjoro Harimurti, Ikhwan Rinaldi, Eric Daniel Tenda, Andhika Rachman, Suryo Anggoro Kusumo Wibowo

    Introduction: Patients with Chronic Kidney Disease (CKD) undergoing regular hemodialysis experience various metabolic changes, including premature aging marked by increased prevalence of frailty. Beta-2 microglobulin (B2M), a uremic toxin whose concentration significantly increases in hemodialysis patients, has emerged as a potential biomarker of frailty. Previous evidence suggests potential link between B2M and frailty in older adults. However, data on its relationship with frailty in hemodialysis patients remains limited. Purpose: To determine the relationship between B2M concentration and frailty in hemodialysis patients. Patients and Methods: This is a cross-sectional study utilizing primary data from hemodialysis patients at Rumah Sakit Cipto Mangunkusumo (RSCM), employing a total sampling method. Beta-2 microglobulin was measured using the Enzyme-Linked Fluorescent Assay (ELFA) method. Frailty was assessed using the Frailty Index 40-item. Medical history was obtained from medical records and interviews. Chi-square tests were performed to determine the relationship between B2M and frailty. Multivariate analysis was conducted to determine variables that affect frailty. Results: A total of 79 subjects participated in the study. The median B2M concentration was 32.8 (IQR 29.8– 36.77). Higher B2M concentration showed a trend toward increased frailty prevalence (PR of 4.83, 95% CI 0.69– 33.81, p = 0.113). The final multivariate analysis showed that sarcopenia (PR 5.37; 95% CI 2.88– 10.04) was strongly and consistently associated with frailty prevalence. Conclusion: Higher B2M showed a trend towards increased frailty prevalence; however, this association is not statistically significant. Sarcopenia is a significant factor influencing the prevalence of frailty in hemodialysis patients.


  • Open Access

    Non‐Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol‐Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial

    by Simon D. Roger, Chew Ming Wong, Phisitt Vejakama, Kuspudji Dwitanto Rahardjo, Bang‐Gee Hsu, Chang Meng Lee, I‐Wen Wu, Tunggul Diapari Situmorang, Pajaree Krisanapan, Sadanah Aqashiah Mazlan, et al.

    Aim: Efepoetin alfa, a novel long‐acting erythropoietin (EPO)‐hybrid Fc fusion protein, represents a promising erythropoiesis‐stimulating agent (ESA) for addressing anaemia in chronic kidney disease (CKD) patients. This Phase 3 trial was to assess the efficacy and tolerability of subcutaneous efepoetin alfa in comparison to subcutaneous methoxy polyethylene glycol‐epoetin beta in stage 3 or 4 CKD patients.Methods: A randomised, multicentre, open‐label Phase 3 trial enrolled 391 CKD stage 3 or stage 4 patients. Subjects underwent a 20‐week correction period followed by an 8‐week evaluation period. Responders continued treatment for an extra 24‐week extension to evaluate long‐term safety, maintenance effectiveness, and the longer treatment interval.Results: In the efepoetin alfa Q2W (every 2 weeks) group, the response rate was 75.6%; while in the methoxy polyethylene glycol‐epoetin beta Q2W group, the response rate was 69.3%. The difference in the response rate was 6.3% with 95% CI (confidence interval) –3.1% to 15.5%. The lower limit of the 95% CI was above the prespecified non‐inferiority margin of −9.0%. Adverse event rates were comparable between the treatment groups.Conclusion: Efepoetin alfa demonstrated non‐inferiority to methoxy polyethylene glycol‐epoetin beta in correcting anaemia and maintaining haemoglobin (Hb) levels among stage 3 and 4 CKD patients. Moreover, the safety profile of efepoetin alfa was comparable to methoxy polyethylene glycol‐epoetin beta.


    • 1 April 2025
      • Vol. 57  (2) , 167-174

    Correlation of Short Chain Fatty Acid (SCFA) Levels with Transient Elastography Values and Controlled Attenuation Parameters in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD).

    by Desi Astari, Chyntia Olivia Maurine Jasirwan, Cosmas Rinaldi Adithya Lesmana, Marcellus Simadibrata, Juferdy Kurniawan, Evy Yunihastuti, Kuntjoro Harimurti, Pringgodigdo Nugroho

    The current hypothesis regarding the mechanism of Non-Alcoholic Fatty Liver Disease (NAFLD) is the multiple hit theory, where one of the factors involved is gut microbiota. Short-chain fatty acid (SCFA) is the main metabolite of gut microbiota and is suspected to play a role in the development of NAFLD. This study aims to determine the correlation between SCFA levels (acetate, propionate, butyrate) and the degree of fibrosis and steatosis in patients with NAFLD assessed by controlled attenuation parameter (CAP) and transient elastography (TE). A cross-sectional study that included 33 consecutively selected patients at Cipto Mangunkusumo Hospital was conducted from January to August 2023. Fecal sample collection was performed for SCFA examination using GC-MS (Gas Chromatography-Mass Spectrometry). Absolute fecal SCFAs were analyzed for correlation with steatosis and fibrosis based on controlled attenuation parameter (CAP) and transient elastography (TE) values. Subjects were predominantly female (51.5%), with an average age of 49 years, an average CAP value of 296 dB/m, and a median transient elastography value of 6.1 kPa. The ratio of acetate, propionate, and butyrate values in the subjects was 59:24:17. A moderate negative correlation was observed between the absolute butyrate and CAP values (r=-0.522; p=0.002). There is no correlation was identified between short-chain fatty acid levels and transient elastography values.